PICO Portalanswers from OpenAlex & ORCID
Ann D. Thor
ResearcherPublications, citations & collaboration network
Ann D. Thor is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Ann D. Thor have?
PICO Portalindexed works
Ann D. Thor has 298 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ann D. Thor have?
PICO Portalcitation count
Ann D. Thor has 22,956 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Ann D. Thor?
PICO Portalh-index
Ann D. Thor has an h-index of 76 in OpenAlex.
What is the i10-index of Ann D. Thor?
PICO Portali10-index
Ann D. Thor has an i10-index of 177 in OpenAlex.
What is the ORCID of Ann D. Thor?
PICO Portalorcid
The ORCID for Ann D. Thor is on the source record.
What is the OpenAlex record for Ann D. Thor?
PICO Portalopenalex
The OpenAlex for Ann D. Thor is on the source record.
What are the most-cited papers on Ann D. Thor?
PICO Portalmost cited works
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
S. Eva Singletary, Craig Allred, Pandora Ashley, Lawrence W. Bassett, Donald A. Berry, Kirby I. Bland, Patrick I. Borgen, Gary M. Clark, Stephen B. Edge, Daniel F. Hayes, Lorie L. Hughes, R. V. P. Hutter, Monica Morrow, David L. Page, Abram Recht, Richard L. Theriault, Ann D. Thor, Donald L. Weaver, H. Samuel Wieand, Frederick L. Greene
Prognostic Factors in Breast Cancer
Patrick L. Fitzgibbons, David L. Page, Donald L. Weaver, Ann D. Thor, D. Craig Allred, Gary M. Clark, Stephen G. Ruby, Frances P. O’Malley, Jean F. Simpson, James L. Connolly, Daniel F. Hayes, Stephen B. Edge, Allen S. Lichter, Stuart J. Schnitt
Accumulation of p53 Tumor Suppressor Gene Protein: An Independent Marker of Prognosis in Breast Cancers
Ann D. Thor, Dan H. Moore, S M Edgerton, Ernest S. Kawasaki, Ellen Reihsaus, Henry T. Lynch, Joseph Marcus, L. Schwartz, L.-C. Chen, Brian H. Mayall, Helene S. Smith
Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
Bryan P. Schneider, Μolin Wang, Milan Radovich, George W. Sledge, Sunil Badve, Ann D. Thor, David A. Flockhart, Bradley A. Hancock, Nancy E. Davidson, Julie R. Gralow, Maura N. Dickler, Edith A. Perez, Melody Cobleigh, Tamara Shenkier, Susan M. Edgerton, Kathy D. Miller